FDA approves subcutaneous SKYRIZI for Crohn's disease induction, allowing at-home treatment. Phase 3 data showed 74% of biologic-naive patients reached clinical ...

Tango Therapeutics updates vopimetostat Phase 1/2 Trial results in combination with RAS(ON) inhibitors. Full data available in SEC filing.

Lilly's sofetabart mipitecan achieves 79% response rate in platinum-sensitive ovarian cancer patients, including those with prior PARP inhibitor exposure.

Medpace wins the SCRS Eagle Award for CRO for the second consecutive year, based on ratings from nearly 2,000 global research sites.

Sefaxersen achieves 43% proteinuria reduction in Phase 3 IgA Nephropathy Study, targeting disease mechanisms beyond standard care in kidney disease treatment.

Perspective Therapeutics' lead-212 radiopharmaceutical shows responses in neuroendocrine tumor trial, with interim Phase 1/2a data presented at European nuclear ...

CluePoints returns as defending two-time winner in the Scrip Awards, shortlisted for Best Contract Research Organization category.

Upacicalcet meets primary endpoints in Phase 3 trials for secondary hyperparathyroidism, with 42–44% of patients achieving 30% PTH reduction versus 17% on place ...

WCG's Activation Intelligence targets clinical trial rework by catching document conflicts before activation, saving sites ...

ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase ...

Clinical Solutions appoints three C-suite executives to lead product, finance, and talent functions amid strong first-half ...

A Nature Neuroscience study separates psilocybin's neuroplastic effects from its hallucinogenic ones, and it should reshape ...